Health article writer and researcher; Over 10.000 articles and research papers have been written and published on line, including world wide health, ezine articles, article base, healthblogs, selfgrowth, best before it's news, the karate GB daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as international journal Pharma and Bio science, ISSN 0975-6299.
Polycystic Ovarian Syndrome
Polycystic Ovarian Syndrome is defined as endocrinologic diseases among reproductive-age women caused by undeveloped follicles clumping on the ovaries that interferes with the function of the normal ovaries associated with a high risk for metabolic disorder(1) as resulting of enlarged ovaries(2), leading to hormone imbalance(excessive androgen and anti-müllerian hormone (AMH) )(1)(3)(4)(5), induced Hirsutism(6)(7), reproductive disorder(10(12)), risks of type 2 diabetes(9)(10)(11), metabolic syndrome(10)(12) and early cardiovasular disease(8)(13), acne(10)(14), endometrial cancer(18)(19),weight gain and obesity(15)(16)(17). The syndrome effects over 5% of women population or 1 in 20 women. Unfortunately, according to studies, women with PCOs after the reproductive age, are associated to continuously increase risk of type II diabetes, with no increasing altered glucose tolerance(20), CVD and hypertension(21).
In Traditional Chinese Medicine Perspective
While conventional medicine focus of using synthetic medication to induce ovulation and assisted artificial insemination for infertility couple, if the medicine fail, traditional Chinese medicine views polycystic ovarian syndrome in different approaches. Polycystic ovary syndrome, according to traditional Chinese medicine is a medical condition characterized by accumulative of fluid over a prolonged period of time causes of dampness and phlegms(1247a)(1247b) build up on the ovaries due to the effects of vary differentiations, affecting not only the women’s menstrual cycle, but also ovulation and fertility(1247a)(1247b).
PCOs Treatment according traditional Chinese medicine
Depending to differentiation, most common diagnosis of polycystic ovary syndrome can be classified into
Kidney yin deficiency
Along with common symptoms mentioned above, women with PCOs diagnosed with kidney yin deficiency may also experience yin vacuity induced cold expressive syndrome, including soreness of waist and knees(1848), lassitude(1848) and fatigue(1848), short breath(1848), poor appetite(1848), aversion to cold(184), cold extremities(1848), ringing in the ears(1850), migraine(1849), hearing problems(1850), a dry mouth and throat(1851), pale fingernails(1851), tidal fever(1851)and night sweating(1851), soles(1851) and chest(1851), constipation(1852),,......... as the kidneys no longer perform their functions of regulating fluid in moistening and nourishing organs and tissues of the body. According to TCM, too much cold/raw foods can aggravate the condition.
In the review of the Data base provided by PubMed, kidney yin deficiency may induce functional impairment or metabolic derangements in vital organs/tissues(1853) persuaded a conglomeration of sundry chronic disease state(1853), cognitive dysfunction(1854), vasomotor symptoms(1855),..... leading to accumulation of fluid in the body organ, promoted accentuation of inflammatory development of phlegm.
Kidney yin deficiency has shown to alter amino acid metabolism(1856), energy metabolism(1856) and gut microflora(1856), anovulatory infertility(1857) and
hypertension(1858), hyperinsulinemia(1859) and hyperandrogenia(1859)..... of which related to symptoms of PCOs(1859).
6. Huang lian
Chemical Constutuents(2043)
1. Berberine
2. Colchicine
3. Coptisine
4. Worenine
5. Palmatine
6. Jatrorrhizine
7. Magnoflorine
8. Kutkin
9. Etc.
Berberine and chemical compound found in huang lian and the whole itself have shown a positive effect in reduced risk of diabetes(2041)(2042) and cardiovascular disease(2057)(2039)(2040)(2058) in women with kidney yin deficiency induced PCOs due to their glucose and lipid metabolism responds(2061) on metabolic syndrome(2064)(2069), including glucose level(2061)(2062), insulin resistance(2059)(2060)(2062), hypertensive(2065)(2066), hyperglycaemia[total cholesterol, triglyceride levels, urinary protein excretion, serum creatinine (Scr) and blood urea nitrogen (BUN)](2062)(2063)(2064) anti hyperglycaemic(2042)(2064), obesity(2064)(2067)(2068),.......via immunomodulatory(2070)(2071), antioxidant(2041)(2047)(2048)and anti-inflammatory activities.
Unfotunately, according Shanghai University of Traditional Chinese Medicine, increasing the systemic exposure of Rhizoma coptidis alkaloids(2071) and over doses of all alkaloids, especially berberine(2072) may induce risk of the acute toxicity.
Hu huang Lian or Huang Lian is also known as coptis rhizome. The bitter and cool herb has been used in TCM as anti palette coagulation(2037)(2038), anti arrhythmia(2039)(2040), anti heart failure(2039), anti diabetic(2041)(2042), anti cancer(2044)(2045)(2046), anti inflammatory(2049)(2050) and antioxidant(2048)(2047) advocate and to relief heat toxicity(2051)(2052), indigestion(2053), inflammation of small intestine(2053), diarrhea(2054)(2055), fever(2054), jaundice(2054), insomnia(2056) and relieve pain(2055),,,,,,,,,, as it eliminates empty-Heat and Damp-Heat, clears Heat, etc., by enhancing the functions of heart, large intestine, liver, and stomach channels(2043)
Chemical Constutuents(2043)
1. Berberine
2. Colchicine
3. Coptisine
4. Worenine
5. Palmatine
6. Jatrorrhizine
7. Magnoflorine
8. Kutkin
9. Etc.
Berberine and chemical compound found in huang lian and the whole itself have shown a positive effect in reduced risk of diabetes(2041)(2042) and cardiovascular disease(2057)(2039)(2040)(2058) in women with kidney yin deficiency induced PCOs due to their glucose and lipid metabolism responds(2061) on metabolic syndrome(2064)(2069), including glucose level(2061)(2062), insulin resistance(2059)(2060)(2062), hypertensive(2065)(2066), hyperglycaemia[total cholesterol, triglyceride levels, urinary protein excretion, serum creatinine (Scr) and blood urea nitrogen (BUN)](2062)(2063)(2064) anti hyperglycaemic(2042)(2064), obesity(2064)(2067)(2068),.......via immunomodulatory(2070)(2071), antioxidant(2041)(2047)(2048)and anti-inflammatory activities.
Unfotunately, according Shanghai University of Traditional Chinese Medicine, increasing the systemic exposure of Rhizoma coptidis alkaloids(2071) and over doses of all alkaloids, especially berberine(2072) may induce risk of the acute toxicity.
Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months
References
(1) Adiposity and metabolic dysfunction in polycystic ovary syndrome by Sam S.(PubMed)
(2) A "kiss" before conception: triggering ovulation with kisspeptin-54 may improve IVF by Young SL.(PubMed)
(3.) Androgen hyperfunction and excessive heterosexual hair growth in women, with special attention to the polycystic ovarian syndrome by Lunde O1.(PubMed)
(4) Expression of anti-Müllerian hormone in letrozole rat model of polycystic ovary syndrome by Du DF1, Li XL, Fang F, Du MR.(PubMed)
(5) [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].[Article in Bulgarian] by Parahuleva N, Pehlivanov B, Orbecova M, Deneva T, Uchikova E.(PubMed)
(6) [Current opinions on the etiology and pathophysiology of hirsutism].[Article in Polish] by Krysiak R1, Kedzia A, Okopień B.(PubMed)
(7) The clinical evaluation of hirsutism by Somani N1, Harrison S, Bergfeld WF.(PubMed)
(8) Polycystic ovary syndrome and insulin: our understanding in the past, present and future by Mayer SB1, Evans WS, Nestler JE.(PubMed)
(9) Association of mean platelet volume with androgens and insulin resistance in nonobese patients with polycystic ovary syndrome by Dogan BA1, Arduc A2, Tuna MM1, Karakılıc E1, Dagdelen I1, Tutuncu Y1, Berker D1, Guler S1.(PubMed)
(10) Approach to the patient: contraception in women with polycystic ovary syndrome by Yildiz BO1.(PubMed)
(11) Polycystic ovarian syndrome (PCOS): a significant contributor to the overall burden of type 2 diabetes in women by Talbott EO1, Zborowski JV, Rager JR, Kip KE, Xu X, Orchard TJ.(PubMed)
(12) Prevalence of vitamin D deficiency in Slovak women with polycystic ovary syndrome and its relation to metabolic and reproductive abnormalities by Figurová J1, Dravecká I, Javorský M, Petríková J, Lazúrová I.(PubMed)
(13) Role of Insulin Sensitizers on Cardiovascular Risk Factors in Polycystic Ovarian Syndrome: A Meta-Analysis by Thethi TK1, Katalenich B2, Nagireddy P3, Chabbra P4, Kuhadiya N5, Fonseca V1.(PubMed)
(14) Acne in hirsute women by Lumezi BG1, Pupovci HL1, Berisha VL1, Goçi AU2, Gerqari A3.(PubMed)
(15) Obesity and polycystic ovary syndrome by Naderpoor N1, Shorakae S, Joham A, Boyle J, De Courten B, Teede HJ.(PubMed)
(16) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan by Teede H1, Deeks A, Moran L.(PubMed)
(17) Metabolic Evidence of Diminished Lipid Oxidation in Women WithPolycystic Ovary Syndrome. by Whigham LD1, Butz DE2, Dashti H3, Tonelli M3, Johnson LK1, Cook ME2, Porter WP4, Eghbalnia HR5, Markley JL6, Lindheim SR7, Schoeller DA8, Abbott DH9, Assadi-Porter FM10.(PubMed)
(18) Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis by Barry JA1, Azizia MM1, Hardiman PJ2.(PubMed)
(19) Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study by Gottschau M1, Kjaer SK2, Jensen A1, Munk C1, Mellemkjaer L3.(PubMed)
(20) Polycystic ovary syndrome: metabolic consequences and long-term management by Carmina E1.(PubMed)
(21) Arterial stiffness is increased in asymptomatic nondiabetic postmenopausal women with a polycystic ovary syndrome phenotype by Armeni E1, Stamatelopoulos K, Rizos D, Georgiopoulos G, Kazani M, Kazani A, Kolyviras A, Stellos K, Panoulis K, Alexandrou A, Creatsa M, Papamichael C, Lambrinoudaki I.(PubMed)
(1246) [Clinical study of area of Jiangsu province of polycystic ovarian syndrome correlation distribution of traditional Chinese medicine syndrome type and improper diet]. [Article in Chinese] by Feng Y, Gao YP.(PubMed)
(1247) [Preliminary study on relationship of disease-syndrome-symptom of ovulatory disorder infertility based on factor analysis]. [Article in Chinese] by Li M, Ma K, Shan, J.(PubMed)
(1247a) A Comprehensive Treatment of Polycystic Ovarian Syndrome (PCOS) by Liqin Zhao(1848) ontrolled trail on moxibustion for maintenance hemodialysis patients in deficiency syndrome]. [Article in Chinese] Li N1, Qiu MY, Hao JR, Zhang QM, Wang SH, Liang F, Yin Y, Luan J, Ge GZ, Qin T, Li BQ.(PubMed)
(1849) [Observation on therapeutic effect of the new Bianshi (stone needle) therapy on migraine]. [Article in Chinese] Yin ZJ1, Yan YJ, Bao HL(PubMed)
(1850) [Study on relation of kidney-deficiency with hearing damage and serum trace elements in patients with chronic nephropathy]. [Article in Chinese] by Yu J1, Xu Y, Fu XD.(PubMed)
(1851) [A family survey of syndromes of traditional Chinese medicine in patients with beta-thalassemia]. [Article in Chinese] by Wang WJ1, Wu ZK, Zhang XH, Liu WJ, Liu YM, Fang SP, Wang RX, Zhang C, Li PP, Luo RG.(PubMed)
(1852) The clinical experiences of Dr. CAI Gan in treating chronic constipation by Zhang ZL1, Zhu MP, Liu Q, Lei YX.(PubMed)
(1853) [Analysis of 35 cases of pathology in yin deficiency syndrome]. [Article in Chinese] by Dai HL, Chen ZL, Song QL.(PubMed)
(1854) Liuwei Dihuang decoction facilitates the induction of long-term potentiation (LTP) in senescence accelerated mouse/prone 8 (SAMP8) hippocampal slices by inhibiting voltage-dependent calcium channels (VDCCs) and promoting N-methyl-d-aspartate receptor (NMDA) receptors by Huang Y1, Zhang H, Yang S, Qiao H, Zhou W, Zhang Y.(PubMed)
(1855) Diagnosis of symptomatic postmenopausal women by traditional Chinese medicine practitioners by Zell B1, Hirata J, Marcus A, Ettinger B, Pressman A, Ettinger KM.(PubMed)
(1856) An integrated metabonomic and proteomic study on Kidney-Yin Deficiency Syndrome patients with diabetes mellitus in China by Jiang N1, Liu HF2, Li SD1, Zhou WX1, Zhang YX1, Zhang Q3, Yan XZ3.(PubMed)
(1857) [Preliminary study on relationship of disease-syndrome-symptom of ovulatory disorder infertility based on factor analysis]. [Article in Chinese] by Li M, Ma K, Shan J.(PubMed)
(1858) Traditional chinese medicine syndromes for essential hypertension: a literature analysis of 13,272 patients by Wang J1, Xiong X1, Liu W1.(PubMed)
(1859) [Clinical observation on treatment of hyperinsulinemia and hyperandrogenism anovulatory patient with replenishing kidney-yin drugs]. [Article in Chinese] by Zhou LR1, Yu J.(PubMed)
(2037) Berberine inhibits LPS-induced TF procoagulant activity and expression through NF-κB/p65, Akt and MAPK pathway in THP-1 cells by Gao MY1, Chen L1, Yang L1, Yu X1, Kou JP2, Yu BY3.(PubMed)
(2038) Berberine, a natural lipid-lowering drug, exerts prothrombotic effects on vascular cells by Holy EW1, Akhmedov A, Lüscher TF, Tanner FC.(PubMed)
(2039) Cardiovascular actions of berberine by Lau CW1, Yao XQ, Chen ZY, Ko WH, Huang Y.(PubMed)
(2040) Berberine elicits anti-arrhythmic effects via IK1/Kir2.1 in the rat type 2 diabetic myocardial infarction model by Wang LH1, Yu CH, Fu Y, Li Q, Sun YQ.(PubMed)
(2041)Application of berberine on treating type 2 diabetes mellitus by Pang B1, Zhao LH2, Zhou Q3, Zhao TY1, Wang H1, Gu CJ1, Tong XL1.(PubMed)
(2042) Berberine as a promising anti-diabetic nephropathy drug: An analysis of its effects and mechanisms by Ni WJ1, Ding HH2, Tang LQ3.(PubMed)
(2043) Huang lian(Complementary and Alternative Healing University)
(2044) Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines by Iizuka N1, Miyamoto K, Okita K, Tangoku A, Hayashi H, Yosino S, Abe T, Morioka T, Hazama S, Oka M.(PubMed)
(2045) Suppression of human breast cancer cell metastasis by coptisine in vitro by Li J1, Qiu DM, Chen SH, Cao SP, Xia XL.(PubMed)
(2046) Berberine hydrochloride impact on physiological processes and modulation of twist levels in nasopharyngeal carcinoma CNE-1 cells by Li CH1, Wu DF, Ding H, Zhao Y, Zhou KY, Xu DF.(PubMed)
(2047) Analysis of the antioxidative function of the radioprotective Japanese traditional (Kampo) medicine, hangeshashinto, in an aqueous phase by Matsumoto C1, Sekine-Suzuki E2, Nyui M3, Ueno M3, Nakanishi I3, Omiya Y4, Fukutake M1, Kase Y4, Matsumoto KI5.(PubMed)
(2048) Characterization, antibacterial, antioxidant, and cytotoxic activities of ZnO nanoparticles using Coptidis Rhizoma by Nagajyothi PC1, Sreekanth TV2, Tettey CO1, Jun YI1, Mook SH3.(PubMed)
(2049) Coptisine attenuates obesity-related inflammation through LPS/TLR-4-mediated signaling pathway in Syrian golden hamsters by Zou ZY1, Hu YR1, Ma H1, Wang YZ1, He K1, Xia S1, Wu H2, Xue DF2, Li XG3, Ye XL4.(PubMed)
(2050) [Progress of berberine for treatment of type 2 diabetes]. [Article in Chinese] by Deng XW, Xie N.(PubMed)
(2051) Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations by Tang J1, Feng Y, Tsao S, Wang N, Curtain R, Wang Y.(PubMed)
(2052) Safety evaluation of main alkaloids from Rhizoma Coptidis by Yi J1, Ye X, Wang D, He K, Yang Y, Liu X, Li X.(PubMed)
(2053) Effects of San-Huang-Xie-Xin-tang, a traditional Chinese prescription for clearing away heat and toxin, on the pacemaker activities of interstitial cells of Cajal from the murine small intestine by Kim BJ1, Kim H2, Lee GS3, So I4, Kim SJ5.(PubMed)
(2054) Study of the anti-MRSA activity of Rhizoma coptidis by chemical fingerprinting and broth microdilution methods by Luo JY1, Yan D2, Yang MH3.(PubMed)
(2055) Analgesic effect of Coptis chinensis rhizomes (Coptidis Rhizoma) extract on rat model of irritable bowel syndrome by Tjong Y1, Ip S, Lao L, Fong HH, Sung JJ, Berman B, Che C.(PubMed)
(2056) Integrated pharmacokinetics of five protoberberine-type alkaloids in normal and insomnic rats after single and multiple oral administration of Jiao-Tai-Wan by He W1, Liu G1, Cai H1, Sun X1, Hou W1, Zhang P2, Xie Z3, Liao Q4.(PubMed)
(2057) Anti-atherosclerotic action of Ger-Gen-Chyn-Lian-Tang and AMPK-dependent lipid lowering effect in hepatocytes. Ho FM1, Liao YH, Yang AJ, Lee Chao PD, Hou YC, Huang CT, Lin SR, Lee KR, Huang KC, Lin WW.(PubMed)
(2058) Coptisine exert cardioprotective effect through anti-oxidative and inhibition of RhoA/Rho kinase pathway on isoproterenol-induced myocardial infarction in rats by Gong LL1, Fang LH, Wang SB, Sun JL, Qin HL, Li XX, Wang SB, Du GH.(PubMed)
(2059) Effect of Coptidis Rhizoma extracts in a water-based solution on insulin resistance in 3T3-L1 adipocytes by Yuan Y1, Wang X, Lu X, Marunaka Y, Wang X.(PubMed)
(2060) Letrozole, berberine, or their combination for anovulatory infertility in women with polycystic ovary syndrome: study design of a double-blind randomised controlled trial by Li Y1, Kuang H, Shen W, Ma H, Zhang Y, Stener-Victorin E, Hung E, Ng Y, Liu J, Kuang H, Hou L, Wu X.(PubMed)
(2061) Gut microbes and Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice by Xie W1, Gu D, Li J, Cui K, Zhang Y.(PubMed)
(2062) Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin by Wu D1, Wen W, Qi CL, Zhao RX, Lü JH, Zhong CY, Chen YY.(PubMed)
(2063) Jiao tai wan attenuates hepatic lipid accumulation in type 2 diabetes mellitus by Huang Z1, Xu X, Lu F, Wang N, Chen G, Zhao Y, Zou X, Wang K, Dong H, Xu L.(PubMed)
(2064) Traditional chinese medicine in treatment of metabolic syndrome by Yin J1, Zhang H, Ye J. (PubMed)
(2065) Simultaneous determination of ten alkaloids of crude and wine-processed Rhizoma Coptidis aqueous extracts in rat plasma by UHPLC-ESI-MS/MS and its application to a comparative pharmacokinetic study by Qian XC1, Zhang L2, Tao Y3, Huang P1, Li JS4, Chai C3, Li W5, Di LQ1, Cai BC3.(PubMed)
(2066) Effects of San-Huang-Xie-Xin-Tang on U46619-induced increase in pulmonary arterial blood pressure by Tsai HH1, Chen IJ, Lo YC.(PubMed)
(2067) Coptis chinensis alkaloids exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating C/EBP-α and PPAR-γ by Choi JS1, Kim JH2, Ali MY1, Min BS3, Kim GD4, Jung HA5.(PubMed)
(2068) [Pharmacodyamic material basis of rhizoma coptidis on insulin resistance]. [Article in Chinese] by Li J1, Meng X, Fan X, Lai X, Zhang Y, Zeng Y.(PubMed)
(2069) Inhibition of preadipocyte differentiation and lipid accumulation by Orengedokuto treatment of 3T3-L1 cultures. Ikarashi N1, Tajima M, Suzuki K, Toda T, Ito K, Ochiai W, Sugiyama K.(PubMed)
(2070) Potential ex vivo immunomodulatory effects of San-Huang-Xie-Xin-Tang and its component herbs on mice and humans by Li CY1, Hou YC, Lee Chao PD, Shia CS, Hsu IC, Fang SH.(PubMed)
(2071) Lipopolysaccharide increased the acute toxicity of the Rhizoma coptidis extract in mice by increasing the systemic exposure to Rhizoma coptidis alkaloids by Ma BL1, Ma YM, Gao CL, Wu JS, Qiu FR, Wang CH, Wang XH.(PubMed)
(2038) Berberine, a natural lipid-lowering drug, exerts prothrombotic effects on vascular cells by Holy EW1, Akhmedov A, Lüscher TF, Tanner FC.(PubMed)
(2039) Cardiovascular actions of berberine by Lau CW1, Yao XQ, Chen ZY, Ko WH, Huang Y.(PubMed)
(2040) Berberine elicits anti-arrhythmic effects via IK1/Kir2.1 in the rat type 2 diabetic myocardial infarction model by Wang LH1, Yu CH, Fu Y, Li Q, Sun YQ.(PubMed)
(2041)Application of berberine on treating type 2 diabetes mellitus by Pang B1, Zhao LH2, Zhou Q3, Zhao TY1, Wang H1, Gu CJ1, Tong XL1.(PubMed)
(2042) Berberine as a promising anti-diabetic nephropathy drug: An analysis of its effects and mechanisms by Ni WJ1, Ding HH2, Tang LQ3.(PubMed)
(2043) Huang lian(Complementary and Alternative Healing University)
(2044) Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines by Iizuka N1, Miyamoto K, Okita K, Tangoku A, Hayashi H, Yosino S, Abe T, Morioka T, Hazama S, Oka M.(PubMed)
(2045) Suppression of human breast cancer cell metastasis by coptisine in vitro by Li J1, Qiu DM, Chen SH, Cao SP, Xia XL.(PubMed)
(2046) Berberine hydrochloride impact on physiological processes and modulation of twist levels in nasopharyngeal carcinoma CNE-1 cells by Li CH1, Wu DF, Ding H, Zhao Y, Zhou KY, Xu DF.(PubMed)
(2047) Analysis of the antioxidative function of the radioprotective Japanese traditional (Kampo) medicine, hangeshashinto, in an aqueous phase by Matsumoto C1, Sekine-Suzuki E2, Nyui M3, Ueno M3, Nakanishi I3, Omiya Y4, Fukutake M1, Kase Y4, Matsumoto KI5.(PubMed)
(2048) Characterization, antibacterial, antioxidant, and cytotoxic activities of ZnO nanoparticles using Coptidis Rhizoma by Nagajyothi PC1, Sreekanth TV2, Tettey CO1, Jun YI1, Mook SH3.(PubMed)
(2049) Coptisine attenuates obesity-related inflammation through LPS/TLR-4-mediated signaling pathway in Syrian golden hamsters by Zou ZY1, Hu YR1, Ma H1, Wang YZ1, He K1, Xia S1, Wu H2, Xue DF2, Li XG3, Ye XL4.(PubMed)
(2050) [Progress of berberine for treatment of type 2 diabetes]. [Article in Chinese] by Deng XW, Xie N.(PubMed)
(2051) Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations by Tang J1, Feng Y, Tsao S, Wang N, Curtain R, Wang Y.(PubMed)
(2052) Safety evaluation of main alkaloids from Rhizoma Coptidis by Yi J1, Ye X, Wang D, He K, Yang Y, Liu X, Li X.(PubMed)
(2053) Effects of San-Huang-Xie-Xin-tang, a traditional Chinese prescription for clearing away heat and toxin, on the pacemaker activities of interstitial cells of Cajal from the murine small intestine by Kim BJ1, Kim H2, Lee GS3, So I4, Kim SJ5.(PubMed)
(2054) Study of the anti-MRSA activity of Rhizoma coptidis by chemical fingerprinting and broth microdilution methods by Luo JY1, Yan D2, Yang MH3.(PubMed)
(2055) Analgesic effect of Coptis chinensis rhizomes (Coptidis Rhizoma) extract on rat model of irritable bowel syndrome by Tjong Y1, Ip S, Lao L, Fong HH, Sung JJ, Berman B, Che C.(PubMed)
(2056) Integrated pharmacokinetics of five protoberberine-type alkaloids in normal and insomnic rats after single and multiple oral administration of Jiao-Tai-Wan by He W1, Liu G1, Cai H1, Sun X1, Hou W1, Zhang P2, Xie Z3, Liao Q4.(PubMed)
(2057) Anti-atherosclerotic action of Ger-Gen-Chyn-Lian-Tang and AMPK-dependent lipid lowering effect in hepatocytes. Ho FM1, Liao YH, Yang AJ, Lee Chao PD, Hou YC, Huang CT, Lin SR, Lee KR, Huang KC, Lin WW.(PubMed)
(2058) Coptisine exert cardioprotective effect through anti-oxidative and inhibition of RhoA/Rho kinase pathway on isoproterenol-induced myocardial infarction in rats by Gong LL1, Fang LH, Wang SB, Sun JL, Qin HL, Li XX, Wang SB, Du GH.(PubMed)
(2059) Effect of Coptidis Rhizoma extracts in a water-based solution on insulin resistance in 3T3-L1 adipocytes by Yuan Y1, Wang X, Lu X, Marunaka Y, Wang X.(PubMed)
(2060) Letrozole, berberine, or their combination for anovulatory infertility in women with polycystic ovary syndrome: study design of a double-blind randomised controlled trial by Li Y1, Kuang H, Shen W, Ma H, Zhang Y, Stener-Victorin E, Hung E, Ng Y, Liu J, Kuang H, Hou L, Wu X.(PubMed)
(2061) Gut microbes and Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice by Xie W1, Gu D, Li J, Cui K, Zhang Y.(PubMed)
(2062) Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin by Wu D1, Wen W, Qi CL, Zhao RX, Lü JH, Zhong CY, Chen YY.(PubMed)
(2063) Jiao tai wan attenuates hepatic lipid accumulation in type 2 diabetes mellitus by Huang Z1, Xu X, Lu F, Wang N, Chen G, Zhao Y, Zou X, Wang K, Dong H, Xu L.(PubMed)
(2064) Traditional chinese medicine in treatment of metabolic syndrome by Yin J1, Zhang H, Ye J. (PubMed)
(2065) Simultaneous determination of ten alkaloids of crude and wine-processed Rhizoma Coptidis aqueous extracts in rat plasma by UHPLC-ESI-MS/MS and its application to a comparative pharmacokinetic study by Qian XC1, Zhang L2, Tao Y3, Huang P1, Li JS4, Chai C3, Li W5, Di LQ1, Cai BC3.(PubMed)
(2066) Effects of San-Huang-Xie-Xin-Tang on U46619-induced increase in pulmonary arterial blood pressure by Tsai HH1, Chen IJ, Lo YC.(PubMed)
(2067) Coptis chinensis alkaloids exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating C/EBP-α and PPAR-γ by Choi JS1, Kim JH2, Ali MY1, Min BS3, Kim GD4, Jung HA5.(PubMed)
(2068) [Pharmacodyamic material basis of rhizoma coptidis on insulin resistance]. [Article in Chinese] by Li J1, Meng X, Fan X, Lai X, Zhang Y, Zeng Y.(PubMed)
(2069) Inhibition of preadipocyte differentiation and lipid accumulation by Orengedokuto treatment of 3T3-L1 cultures. Ikarashi N1, Tajima M, Suzuki K, Toda T, Ito K, Ochiai W, Sugiyama K.(PubMed)
(2070) Potential ex vivo immunomodulatory effects of San-Huang-Xie-Xin-Tang and its component herbs on mice and humans by Li CY1, Hou YC, Lee Chao PD, Shia CS, Hsu IC, Fang SH.(PubMed)
(2071) Lipopolysaccharide increased the acute toxicity of the Rhizoma coptidis extract in mice by increasing the systemic exposure to Rhizoma coptidis alkaloids by Ma BL1, Ma YM, Gao CL, Wu JS, Qiu FR, Wang CH, Wang XH.(PubMed)
